Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
AdipoGen Life Sciences
GW1929
60
CHF
CHF 60.00
In stock
AG-CR1-0116-M0011 mgCHF 60.00
AG-CR1-0116-M0055 mgCHF 160.00
AG-CR1-0116-M02525 mgCHF 560.00
| Product Details | |
|---|---|
| Synonyms | N-(2-Benzoylphenyl)-L-tyrosine PPARγ Agonist; (2S)-((2-Benzoylphenyl)amino-3-[4-[2-(methylpyridin-2-ylamino)ethoxy]phenyl]propionic acid |
| Product Type | Chemical |
| Properties | |
| Formula |
C30H29N3O4 |
| MW | 495.6 |
| CAS | 196808-24-9 |
| Purity Chemicals | ≥98% (HPLC) |
| Appearance | Off-white to yellow crystalline solid. |
| Solubility | Soluble in DMSO or methanol. |
| Identity | Determined by 1H-NMR. |
| InChi Key | QTQMRBZOBKYXCG-MHZLTWQESA-N |
| Smiles | COC1=CC(=O)OC(=C1)C1C2(O)CC3OC(=O)[C@]2(O)C(C(=O)C2=CC=CC=C2)C1(O)C3O |
| Shipping and Handling | |
| Shipping | AMBIENT |
| Short Term Storage | +4°C |
| Long Term Storage | -20°C |
| Handling Advice | Protect from light. |
| Use/Stability |
Stable for at least 2 years after receipt when stored at -20°C. Store solutions at -20°C in the dark. |
| Documents | |
| MSDS |
 Download PDF |
| Product Specification Sheet | |
| Datasheet |
Download PDF |
Description
- Potent and subtype-selective (>1'000-fold) PPARγ agonist [1].
- Angiogenesis inhibitor [3].
- Apoptosis inhibitor [4].
- Anti-inflammatory [4].
- Anti-hyperglycemic and anti-hyperlipidemic agent [1].
- Antidiabetic. The glucose-lowering effect in rats is 100-fold more potent than that of troglitazone [2].
Product References
- N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents: B.R. Henke, et al.; J. Med. Chem. 41, 5020 (1998)
- A novel N-aryl tyrosine activator of peroxisome proliferator-activated receptor-gamma reverses the diabetic phenotype of the Zucker diabetic fatty rat: K.K. Brown, et al.; Diabetes 48, 1415 (1999)
- PPARgamma agonists inhibit angiogenesis by suppressing PKCalpha- and CREB-mediated COX-2 expression in the human endothelium: E. Scoditti, et al.; Cardiovasc. Res. 86, 302 (2010)
- Ameliorative Effects of GW1929, a Nonthiazolidinedione PPAR γ Agonist, on Inflammation and Apoptosis in Focal Cerebral Ischemic-Reperfusion Injury: R.K. Kaundal & S.S. Sharma; Curr. Neurovasc. Res. 8, 236 (2011)
- Reactive fibrosis precedes doxorubicin-induced heart failure through sterile inflammation: R. Tanaka, et al.; ESC Heart Fail. ahead of print (2020)
Related Products
